Answers are grounded in this paper and cite their sources.
Alport syndrome (AS) is a hereditary glomerular disease caused by pathogenic variants in the COL4A3 , COL4A4 , or COL4A5 genes, which encode essential components of the type IV collagen network. Advances in genomic sequencing and molecular diagnostics have expanded the recognized spectrum of AS beyond its classical severe forms to a broader range of COL4A3–COL4A5-related disorders. Mechanistic research has moved beyond structural defects of the glomerular basement membrane (GBM) to reveal a multilayered pathogenic network involving abnormal GBM biomechanics, cellular crosstalk, extracellular matrix (ECM) defects and intracellular proteostasis stress, and signaling pathways that drive disease progress. In parallel, diagnosis has shifted from pathology-based recognition toward genetics-first testing of COL4A3–COL4A5 . Therapeutic strategies are also expanding beyond general kidney protection toward risk-adapted and mechanism-informed interventions. This review summarizes recent advances in the genetic spectrum, molecular mechanisms, genotype–phenotype relationships, diagnostic strategies, and therapeutic development of AS, and discusses a clinical management framework that integrates genetic risk with longitudinal changes in albuminuria and estimated glomerular filtration rate (eGFR) to guide dynamic risk assessment, individualized monitoring, and treatment throughout life.
No takes yet. Share an insight, caveat, or question.
An et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: